Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α. [electronic resource]
Producer: 20190924Description: 847-857 p. digitalISSN:- 1557-3265
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Cell Line
- Cell Line, Tumor
- Child
- Disease-Free Survival
- Humans
- Mice, Nude
- Receptor, Platelet-Derived Growth Factor alpha -- antagonists & inhibitors
- Sarcoma -- drug therapy
- Soft Tissue Neoplasms -- drug therapy
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.